PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary

Ewing sarcoma (ES) is an aggressive pediatric bone tumor that is prone to metastasis. Due to low five-year survival rates and limited therapeutic options for metastatic disease, there is a dire clinical need for improved ES treatments. Targeting p21-activated kinases (PAKs) may be key. PAK1 and PAK4...

Descripción completa

Detalles Bibliográficos
Autores principales: Parks, Sydney E., Yustein, Jason T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802585/
https://www.ncbi.nlm.nih.gov/pubmed/36594908
http://dx.doi.org/10.46439/cancerbiology.2.032
_version_ 1784861706456924160
author Parks, Sydney E.
Yustein, Jason T.
author_facet Parks, Sydney E.
Yustein, Jason T.
author_sort Parks, Sydney E.
collection PubMed
description Ewing sarcoma (ES) is an aggressive pediatric bone tumor that is prone to metastasis. Due to low five-year survival rates and limited therapeutic options for metastatic disease, there is a dire clinical need for improved ES treatments. Targeting p21-activated kinases (PAKs) may be key. PAK1 and PAK4 are associated with aggressive ES and poor patient outcomes, although their molecular mechanisms remain largely uncharacterized in this disease. This commentary aims to highlight the recent advancements made to the understanding of PAK1 and PAK4 in ES in the paper “p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma” by Qasim et al.
format Online
Article
Text
id pubmed-9802585
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-98025852022-12-30 PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary Parks, Sydney E. Yustein, Jason T. J Cancer Biol Article Ewing sarcoma (ES) is an aggressive pediatric bone tumor that is prone to metastasis. Due to low five-year survival rates and limited therapeutic options for metastatic disease, there is a dire clinical need for improved ES treatments. Targeting p21-activated kinases (PAKs) may be key. PAK1 and PAK4 are associated with aggressive ES and poor patient outcomes, although their molecular mechanisms remain largely uncharacterized in this disease. This commentary aims to highlight the recent advancements made to the understanding of PAK1 and PAK4 in ES in the paper “p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma” by Qasim et al. 2021 /pmc/articles/PMC9802585/ /pubmed/36594908 http://dx.doi.org/10.46439/cancerbiology.2.032 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Parks, Sydney E.
Yustein, Jason T.
PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
title PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
title_full PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
title_fullStr PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
title_full_unstemmed PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
title_short PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
title_sort pak1 and pak4 as therapeutic targets for ewing sarcoma: a commentary
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802585/
https://www.ncbi.nlm.nih.gov/pubmed/36594908
http://dx.doi.org/10.46439/cancerbiology.2.032
work_keys_str_mv AT parkssydneye pak1andpak4astherapeutictargetsforewingsarcomaacommentary
AT yusteinjasont pak1andpak4astherapeutictargetsforewingsarcomaacommentary

Ejemplares similares